HDAC9 and cancer: Because of the powerful impact of epigenetic drugs on gene expression and the potential side effects with prolonged administration, we have chosen a short treatment paradigm in mice (i.p., once daily for 3 days), which was based on a similar regimen used in human cancer treatment with the FDA‐approved HDAC inhibitor romidepsin (i.v., once a week for 1 month).